Trials / Completed
CompletedNCT06196580
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
A Clinical Study Evaluating the Pharmacokinetic Effects of SHR4640 on Repaglinide and Midazolam in Healthy Subjects and the Impact of SHR4640 on QT Interval
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the PK effects of SHR4640 tablets on repaglinide and midazolam, as well as the effects of SHR4640 tablets on the QT interval in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | repaglinide; midazolam; SHR4640 | repaglinide; midazolam; SHR4640 |
| DRUG | repaglinide; midazolam; SHR4640; SHR4640 placebo | repaglinide; midazolam; SHR4640; SHR4640 placebo |
| DRUG | repaglinide; midazolam; SHR4640 placebo | repaglinide; midazolam; SHR4640 placebo |
Timeline
- Start date
- 2024-01-04
- Primary completion
- 2024-02-16
- Completion
- 2024-02-16
- First posted
- 2024-01-09
- Last updated
- 2024-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06196580. Inclusion in this directory is not an endorsement.